S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy

argenx Stock Price, News & Analysis (NASDAQ:ARGX)

$453.89
+3.28 (+0.73%)
(As of 12/1/2023 ET)
Compare
Today's Range
$447.30
$454.98
50-Day Range
$435.92
$508.78
52-Week Range
$333.07
$550.76
Volume
283,405 shs
Average Volume
260,516 shs
Market Capitalization
$26.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$546.00

argenx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
20.3% Upside
$546.00 Price Target
Short Interest
Healthy
1.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.20mentions of argenx in the last 14 days
Based on 47 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.79) to ($2.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

758th out of 953 stocks

Biotechnology Industry

13th out of 21 stocks


ARGX stock logo

About argenx Stock (NASDAQ:ARGX)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Stock Price History

ARGX Stock News Headlines

Morgan Stanley Lowers argenx (NASDAQ:ARGX) Price Target to $586.00
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Several Catalysts Pushed argenx SE (ARGX) in Q3
argenx (NASDAQ:ARGX) PT Lowered to $550.00
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
argenx (NASDAQ:ARGX) PT Lowered to $591.00 at Citigroup
Analyst Ratings for argenx
Argenx drug meets surprise late-stage failure
Why Is Dutch Pharma Argenx Trading Lower Today?
argenx SE ARGX
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
843
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$546.00
High Stock Price Target
$628.00
Low Stock Price Target
$435.00
Potential Upside/Downside
+20.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
20 Analysts

Profitability

Net Income
$-709,590,000.00
Pretax Margin
-52.69%

Debt

Sales & Book Value

Annual Sales
$445.27 million
Book Value
$50.79 per share

Miscellaneous

Free Float
57,643,000
Market Cap
$26.82 billion
Optionable
Optionable
Beta
0.72
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Timothy Van Hauwermeiren EMBA (Age 51)
    M.B.A., M.Sc., CEO & Executive Director
    Comp: $1.44M
  • Mr. Karl Gubitz (Age 53)
    Chief Financial Officer
  • Ms. Malini Moorthy (Age 53)
    General Counsel
  • Mr. Arjen Lemmen M.Sc. (Age 38)
    Vice President of Corporate Development & Strategy
  • Ms. Andria Wilk (Age 49)
    Global Head of Quality
  • Mr. Luc Truyen (Age 58)
    Chief Medical Officer
  • Ms. Karen Massey (Age 44)
    Chief Operating Officer
  • Mr. Filip Borgions
    VP & Global Head of Technical Operations
  • Mr. Peter Ulrichts (Age 43)
    Chief Scientific Officer
  • Ms. Beth DelGiacco
    VP and Global Head of Corporate Communications & Investor Relations














ARGX Stock Analysis - Frequently Asked Questions

Should I buy or sell argenx stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 sell rating, 2 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings
or view top-rated stocks.

What is argenx's stock price target for 2024?

20 analysts have issued 12 month price targets for argenx's shares. Their ARGX share price targets range from $435.00 to $628.00. On average, they expect the company's share price to reach $546.00 in the next year. This suggests a possible upside of 20.3% from the stock's current price.
View analysts price targets for ARGX
or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2023?

argenx's stock was trading at $378.83 at the beginning of the year. Since then, ARGX stock has increased by 19.8% and is now trading at $453.89.
View the best growth stocks for 2023 here
.

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our ARGX earnings forecast
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its quarterly earnings results on Tuesday, October, 31st. The company reported ($1.25) earnings per share for the quarter, beating analysts' consensus estimates of ($1.48) by $0.23. The company earned $339.84 million during the quarter, compared to analyst estimates of $310.06 million. argenx had a negative net margin of 22.70% and a negative trailing twelve-month return on equity of 12.40%. During the same period in the previous year, the business posted ($4.26) earnings per share.

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are argenx's major shareholders?

argenx's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (8.40%), Artisan Partners Limited Partnership (4.79%), Jennison Associates LLC (2.56%), Massachusetts Financial Services Co. MA (0.98%), Morgan Stanley (0.94%) and RTW Investments LP (0.86%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ARGX) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -